Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors
NCT07227168Phase 1Recruiting
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of STRO-004 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer and 6 more (3 arms), sponsored by Sutro Biopharma, Inc. Primary endpoints: Dose-limiting Toxicities at Day 21, Treatment-Emergent Adverse Events at 12 months and 6 more. Started Nov 2025; status: recruiting.
02
Drugs
STRO-004
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07227168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227168.